Fedha

Hisa unazofuatilia
Kwa nini AMGN imeongezeka kwa 3.29%?
Fahamu zaidi
AMGN:NASDAQ
Amgen Inc
US$ 438.94
+3.29%
(+14.00) Siku 1
US$ 435.70
-0.74% (-3.24)
Baada ya saa
Imefungwa: 20 Okt, 16:00:01 GMT -4  ·   USD
Alama zote
AlamaBeiTofautiTofauti ya asilimia
Inatayarisha maarifa maarufu ya AMGN...
Fungua
US$ 425.58
Juu
US$ 439.05
Chini
US$ 425.11
Mtaji wa soko
237.31B
Wastani wa kiasi cha mauzo
3.14M
Kiasi cha mauzo ya hisa
0.00
Gawio
2.30%
Mgawo wa faida wa kila robo mwaka
US$ 2.52
Tarehe ya kutojumuisha gawio
21 Ago 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
27.26
Juu kwa wiki 52
US$ 447.01
Chini kwa wiki 52
US$ 288.00
EPS
US$ 16.10
Beta
0.41
Hisa za wawekezaji
540.63M
Idadi ya wafanyakazi
elfu 32
Fungua
US$ 425.58
Juu
US$ 439.05
Chini
US$ 425.11
Mtaji wa soko
237.31B
Wastani wa kiasi cha mauzo
3.14M
Kiasi cha mauzo ya hisa
0.00
Gawio
2.30%
Mgawo wa faida wa kila robo mwaka
US$ 2.52
Tarehe ya kutojumuisha gawio
21 Ago 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
27.26
Juu kwa wiki 52
US$ 447.01
Chini kwa wiki 52
US$ 288.00
EPS
US$ 16.10
Beta
0.41
Hisa za wawekezaji
540.63M
Idadi ya wafanyakazi
elfu 32
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Wasifu
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
Kuhusu Amgen Inc
Afisa Mkuu Mtendaji (CEO)Robert A. Bradway
Wafanyakazielfu 31.5
Lilianzishwa1980
Makao makuuThousand Oaks, California, Marekani
Sekta-
Tovutiamgen.com
Ukadiriaji wa mchanganuzi
Kulingana na wachanganuzi 27 waliotoa ukadiriaji wa hisa kwa AMGN katika miezi 3 iliyopita
Nunua
Nunua
9
Shikilia
16
Uza
2
Utabiri wa miezi 12
Kulingana na wachanganuzi 27 wa Wall Street wanaotoa makadirio ya bei ya miezi 12 ya AMGN katika miezi 3 iliyopita.
Juu kabisa
Ya sasa US$ 438.94
US$ 500.00 (+13.91%)
Wastani
US$ 403.33 (-8.11%)
Chini kabisa
US$ 230.00 (-47.60%)
Mchanganuzi
Unaopendekezwa
Kitendo
Bei lengwa
Unaokadiriwa
Tarehe
David Amsellem
Piper Sandler
Buy
Reiterated
US$ 457.00
+4.1%
10/20/2026
Mohit Bansal
Wells Fargo
Hold
Maintained
US$ 430.00
-2%
10/15/2026
Vamil Divan
Guggenheim
Hold
Maintained
US$ 378.00
-13.9%
10/12/2026
Evan Seigerman
BMO Capital
Hold
Maintained
US$ 415.00
-5.5%
10/12/2026
Geoff Meacham
Citi
Hold
Maintained
US$ 405.00
-7.7%
10/12/2026
Tazeen Ahmad
Bank of America Securities
Sell
Reiterated
US$ 328.00
-25.3%
10/12/2026
Michael Yee
UBS
Buy
Reiterated
US$ 470.00
+7.1%
10/09/2026
Luca Issi
RBC Capital
Buy
Maintained
US$ 430.00
-2%
10/08/2026
Carter Gould
Cantor Fitzgerald
Hold
Reiterated
US$ 440.00
+0.2%
10/08/2026
Gregory Renza
Truist Financial
Hold
Maintained
US$ 380.00
-13.4%
10/07/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
US$ 359.00
-18.2%
10/07/2026
Louise Chen
Scotiabank
Buy
Maintained
US$ 500.00
+13.9%
09/29/2026
Christopher Raymond
Raymond James
Hold
Maintained
-
-
09/24/2026
Unknown Analyst
Leerink Partners
Hold
Maintained
-
-
09/23/2026
Unknown Analyst
Jefferies
Hold
Maintained
US$ 410.00
-6.6%
09/23/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
US$ 450.00
+2.5%
09/22/2026
Gary Nachman
Canaccord Genuity
Hold
Maintained
US$ 384.00
-12.5%
09/23/2026
Yaron Werber
TD Cowen
Buy
Reiterated
US$ 452.00
+3%
09/22/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/22/2026
Emily Field
Barclays
Hold
Maintained
US$ 380.00
-13.4%
09/17/2026
Morten Herholdt
HSBC
Hold
Downgraded
US$ 425.00
-3.2%
09/09/2026
Jasper Hellweg
Argus Research
Buy
Reiterated
US$ 460.00
+4.8%
08/18/2026
Salim Syed
Mizuho Securities
Hold
Maintained
US$ 352.00
-19.8%
08/17/2026
Chris Schott
J.P. Morgan
Hold
Maintained
US$ 350.00
-20.3%
08/06/2026
Courtney Breen
Bernstein
Hold
Maintained
US$ 345.00
-21.4%
08/05/2026
Jay Olson
Oppenheimer
Buy
Maintained
US$ 450.00
+2.5%
08/05/2026
Brian Skorney
Robert W. Baird
Sell
Maintained
US$ 230.00
-47.6%
08/05/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Upgraded
US$ 375.00
-14.6%
05/07/2026
Hans Engel
Erste Group
Hold
Downgraded
-
-
05/05/2026
Unknown Analyst
Raymond James
Hold
Reiterated
-
-
05/01/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
05/01/2026
Unknown Analyst
J.P. Morgan
Hold
Initiated
US$ 300.00
-31.7%
05/01/2026
Unknown Analyst
Canaccord Genuity
Hold
Initiated
US$ 366.00
-16.6%
04/21/2026
Akash Tewari
Jefferies
Hold
Initiated
US$ 350.00
-20.3%
03/10/2026
Unknown Analyst
Argus Research
Buy
Maintained
US$ 400.00
-8.9%
02/06/2026
Simu inayofuata baada ya siku baada ya siku 14
Jumanne, 3 Nov, 23:30
Kipindi cha Kifedha
Robo3 2026
- / US$ 5.76
Mapato dhidi ya makadirio (USD)
- / 10.06B
Mkutano pepe wa kujadili mapato ya robo ya Robo ya 3 ya mwaka wa fedha wa 2026
Inasubiri mkutano pepe wa kujadili mapato
Kwa muhtasari: mapato yajayo
Maarifa kutoka kwenye ripoti na habari za hivi punde
Ripoti za awaliThamani zote katika USD
Loading Previous Earnings...
Mapato
Mapato halisi
Thamani zote katika USD
Sep 2025
Des 2025
Mac 2026
Jun 2026
Mapato
9.56B
9.87B
8.62B
10.05B
Gharama ya bidhaa zilizouzwa
2.74B
2.68B
2.50B
2.75B
Gharama ya mapato
2.74B
2.68B
2.50B
2.75B
Gharama za utafiti na maendeleo
1.90B
2.14B
1.72B
1.87B
Jumla ya gharama za utafiti na maendeleo
-
-
-
-
Gharama za uuzaji, za jumla na za usimamizi
1.72B
1.95B
1.60B
1.74B
Gharama ya uendeshaji
3.55B
4.18B
3.21B
3.73B
Jumla ya gharama za uendeshaji
6.29B
6.85B
5.70B
6.48B
Mapato ya uendeshaji
3.26B
3.01B
2.91B
3.57B
Mapato mengine yasiyo ya uendeshaji
181.00M
143.00M
192.00M
145.00M
EBT ikijumuisha vipengee visivyo vya kawaida
3.92B
1.51B
2.08B
2.77B
EBT bila kujumuisha vipengee visivyo vya kawaida
2.72B
2.51B
2.37B
3.06B
Gharama ya kodi ya mapato
705.00M
181.00M
265.00M
393.00M
Kiwango cha kodi kinachotumika
17.98%
11.96%
12.72%
14.20%
Gharama nyingine za uendeshaji
-71.00M
82.00M
-113.00M
116.00M
Mapato halisi
3.22B
1.33B
1.82B
2.38B
Kiwango cha faida halisi
33.65%
13.51%
21.11%
23.62%
Mapato kwa kila hisa
5.64
5.29
5.15
6.29
Mapato ya riba na uwekezaji
-
408.00M
-
-
Gharama ya riba
-685.00M
-1.06B
-657.00M
-673.00M
Jumla ya gharama halisi za riba
-685.00M
-653.00M
-657.00M
-673.00M
Gharama za kushuka kwa thamani na za kulipa deni
-
-
-
-
Mapato ya kampuni kabla ya riba, kodi, kushuka thamani na kulipa madeni
4.57B
4.02B
4.03B
4.69B
Faida au hasara kutokana na uuzaji wa vipengee
-
-
-
-
Miamala ya wajuzi wa mambo
Data ya miamala ya watu wenye hisa hutolewa kwenye vyanzo vya washirika wengine. Pata maelezo zaidi
Mjuzi wa mambo
Nafasi
Aina
Tarehe
Hisa
Kiasi
Ukurasa wa 1
Maudhui yaliyotayarishwa kwa AI yanaweza kuwa na makosa. Pata maelezo zaidi
UsaidiziTuma maoniFaraghaSheria na MashartiKanusho
Programu za Google